Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Malin

BATS-CHIXE:MLCi
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MLCi
BATS-CHIXE
€124M
Market Cap
  1. Home
  2. GB
  3. Pharmaceuticals & Biotech
Company description

Malin Corporation plc, through its subsidiaries, operates in the life sciences industry in Spain, rest of European Union, and internationally. The last earnings update was 6 days ago. More info.


Add to Portfolio Compare Print
  • Malin has significant price volatility in the past 3 months.
MLCi Share Price and Events
7 Day Returns
0%
BATS-CHIXE:MLCi
19.9%
GB Life Sciences
10%
GB Market
1 Year Returns
-
BATS-CHIXE:MLCi
-15.8%
GB Life Sciences
-23%
GB Market
MLCi Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Malin (MLCi) 0% -44.3% -47.7% - - -
GB Life Sciences 19.9% -20.4% -32% -15.8% -16.1% -24.9%
GB Market 10% -17.6% -27.3% -23% -24.2% -21.8%
1 Year Return vs Industry and Market
  • No trading data on MLCi.
  • No trading data on MLCi.
Price Volatility
MLCi
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Malin's competitors could be found in our database.

MLCi Value

 Is Malin undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Malin. This is due to cash flow or dividend data being unavailable. The share price is €2.45.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Malin's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Malin's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:MLCi PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-0.12
ISE:MLC Share Price ** ISE (2020-03-16) in EUR €2.7
Europe Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 48.4x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 747 Publicly-Listed Companies 12.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Malin.

BATS-CHIXE:MLCi PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ISE:MLC Share Price ÷ EPS (both in EUR)

= 2.7 ÷ -0.12

-22.95x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Malin is loss making, we can't compare its value to the Europe Life Sciences industry average.
  • Malin is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Malin's expected growth come at a high price?
Raw Data
BATS-CHIXE:MLCi PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -22.95x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Life Sciences Industry PEG Ratio Median Figure of 15 Publicly-Listed Life Sciences Companies 2.05x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 526 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Malin, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Malin's assets?
Raw Data
BATS-CHIXE:MLCi PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €3.69
ISE:MLC Share Price * ISE (2020-03-16) in EUR €2.7
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry PB Ratio Median Figure of 13 Publicly-Listed Life Sciences Companies 1.88x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,322 Publicly-Listed Companies 1.08x
BATS-CHIXE:MLCi PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ISE:MLC Share Price ÷ Book Value per Share (both in EUR)

= 2.7 ÷ 3.69

0.73x

* Primary Listing of Malin.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Malin is good value based on assets compared to the GB Life Sciences industry average.
X
Value checks
We assess Malin's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Malin has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MLCi Future Performance

 How is Malin expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
0%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Malin expected to grow at an attractive rate?
  • Unable to compare Malin's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Malin's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
  • Malin's revenues are expected to decrease over the next 1-3 years, this is below the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:MLCi Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:MLCi Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 0%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 43.5%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average -10.3%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:MLCi Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:MLCi Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 35 -4 1
2020-12-31 35 -7 1
2020-03-31
BATS-CHIXE:MLCi Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 35 -4 -5
2019-09-30 35 -9 -13
2019-06-30 35 -15 -20
2019-03-31 36 -14 -33
2018-12-31 38 -13 -46
2018-09-30 40 -14 -70
2018-06-30 43 -15 -95
2018-03-31 42 -21 -97
2017-12-31 42 -27 -99
2017-09-30 42 -28 -87
2017-06-30 41 -28 -74
2017-03-31 42 -25 -79

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Malin is high growth as no earnings estimate data is available.
  • Malin's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:MLCi Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Malin Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:MLCi Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31
2020-12-31
2020-03-31
BATS-CHIXE:MLCi Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -0.12
2019-09-30 -0.28
2019-06-30 -0.43
2019-03-31 -0.72
2018-12-31 -1.01
2018-09-30 -1.56
2018-06-30 -2.13
2018-03-31 -2.24
2017-12-31 -2.36
2017-09-30 -2.12
2017-06-30 -1.86
2017-03-31 -1.99

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Malin will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Malin's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Malin has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MLCi Past Performance

  How has Malin performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Malin's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Malin does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Malin's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Malin's 1-year growth to the Europe Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
Malin's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Malin Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:MLCi Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 34.90 -5.40 18.80 2.70
2019-09-30 34.85 -12.65 19.00 2.55
2019-06-30 34.80 -19.90 19.20 2.40
2019-03-31 36.40 -33.10 21.35 2.75
2018-12-31 38.00 -46.30 23.50 3.10
2018-09-30 40.40 -70.40 29.30 5.70
2018-06-30 42.80 -94.50 35.10 8.30
2018-03-31 42.35 -96.65 40.00 9.90
2017-12-31 41.90 -98.80 44.90 11.50
2017-09-30 41.55 -86.60 49.05 9.45
2017-06-30 41.20 -74.40 53.20 7.40
2017-03-31 41.65 -78.95 53.05 6.25
2016-12-31 42.10 -83.50 52.90 5.10
2016-06-30 41.14 -51.55 26.75 4.89
2015-12-31 21.14 -41.45 25.75 2.49

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Malin has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Malin has efficiently used its assets last year compared to the Europe Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Malin improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Malin's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Malin has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MLCi Health

 How is Malin's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Malin's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Malin is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Malin's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Malin's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Malin Company Filings, last reported 3 months ago.

BATS-CHIXE:MLCi Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 179.10 68.80 47.50
2019-09-30 179.10 68.80 47.50
2019-06-30 178.40 71.60 34.40
2019-03-31 178.40 71.60 34.40
2018-12-31 170.40 73.10 48.80
2018-09-30 170.40 73.10 48.80
2018-06-30 208.30 61.50 48.70
2018-03-31 208.30 61.50 48.70
2017-12-31 221.40 63.70 32.10
2017-09-30 221.40 63.70 32.10
2017-06-30 299.80 65.90 49.10
2017-03-31 299.80 65.90 49.10
2016-12-31 308.10 67.90 48.90
2016-06-30 321.20 31.20 60.40
2015-12-31 365.40 35.20 97.00
  • Malin's level of debt (38.4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Malin's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Malin has sufficient cash runway for more than 3 years based on current free cash flow.
  • Malin has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -15% each year.
X
Financial health checks
We assess Malin's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Malin has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MLCi Dividends

 What is Malin's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Malin dividends. Estimated to be 0% next year.
If you bought €2,000 of Malin shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Malin's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Malin's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:MLCi Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 12 Stocks 0.7%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 629 Stocks 6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.4%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.7%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:MLCi Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Malin has not reported any payouts.
  • Unable to verify if Malin's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Malin's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Malin has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Malin's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.
X
Income/ dividend checks
We assess Malin's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Malin afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Malin has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MLCi Management

 What is the CEO of Malin's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Darragh Lyons
COMPENSATION €471,392
AGE 38
TENURE AS CEO 1.4 years
CEO Bio

Mr. Darragh Fergal Lyons has been Chief Executive Officer of Malin Corporation plc since September 3, 2019 and serves as its Executive Director since March 24, 2020. Mr. Lyons was Chief Business and Financial Officer at Malin Corp. plc. until September 2019 and has assumed the duties of CEO on October 26, 2018. He has been Chief Financial Officer of Malin Corporation plc since December 19, 2014. Mr. Lyons worked in a number of senior finance positions in Elan, most recently serving as the head of group finance (prior to the sale of Elan to Perrigo) where he was responsible for all aspects of internal and external reporting as well as overseeing the transactional and financing activities. Prior to joining Elan, Mr. Lyons worked with PricewaterhouseCoopers in Dublin, the United States and Canada and also served in its Global Technical Accounting Group. He served as an Executive Director of Malin Corporation plc until July 16, 2018. Mr. Lyons is a shareholder of BPI and is a former Director of Brandon Point Management Services Unlimited Company (trading as “BPI Consulting”). He had Directorships in Harbour Square Corporate Secretaries Limited, 3D4 Medical Limited, Malin Life Sciences (UK) Limited and Brandon Point Management Services Unlimited Company. He has Directorships in Malin Life Sciences International Limited, An2H Discovery Limited, Altan Pharma Limited , Nidus Laboratories Ireland Limited , Hatchill Limited, NeuVT Limited, Emba Medical Limited, Emba Neuro Limited, Neurobiometrix Limited, Serenus Biotherapeutics Limited, Brandon Point Enterprises 1 Limited and Malin Life Sciences (US) Inc. Mr. Lyons is a Fellow of Chartered Accountants Ireland.

CEO Compensation
  • Darragh's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Darragh's remuneration is higher than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Malin management team in years:

1.4
Average Tenure
66
Average Age
  • The average tenure for the Malin management team is less than 2 years, this suggests a new team.
Management Team

Darragh Lyons

TITLE
CEO & Executive Director
COMPENSATION
€471K
AGE
38
TENURE
1.4 yrs

Pat Jennings

TITLE
Chief Financial Officer
TENURE
0.4 yrs

Jessica Bergin

TITLE
Director of Investor Relations & External Reporting

Sean Murphy

TITLE
Executive Vice President
COMPENSATION
€41K
AGE
66

Andy von Eschenbach

TITLE
Chief Medical Adviser
AGE
77
TENURE
2.4 yrs

Fiona Dunlevy

TITLE
Company Secretary
TENURE
1.4 yrs
Board of Directors Tenure

Average tenure and age of the Malin board of directors in years:

1.7
Average Tenure
57
Average Age
  • The average tenure for the Malin board of directors is less than 3 years, this suggests a new board.
Board of Directors

Liam Daniel

TITLE
Non-Executive Chairman
COMPENSATION
€72K
AGE
67
TENURE
0.6 yrs

Darragh Lyons

TITLE
CEO & Executive Director
COMPENSATION
€471K
AGE
38

Jean-Michel Cosséry

TITLE
Independent Non-Executive Director
COMPENSATION
€34K
AGE
59
TENURE
1.7 yrs

Rudy Mareel

TITLE
Lead Independent Non-Executive Director
COMPENSATION
€35K
AGE
55
TENURE
1.7 yrs

Kirsten Drejer

TITLE
Independent Non-Executive Director
AGE
63

Luke Corning

TITLE
Non-Executive Director
AGE
37
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Malin's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Malin has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MLCi News

Simply Wall St News

MLCi Company Info

Description

Malin Corporation plc, through its subsidiaries, operates in the life sciences industry in Spain, rest of European Union, and internationally. The company offers life-saving therapeutics for patients with high unmet medical need; biological therapies, which focuses on oncology, infectious, and autoimmune diseases; and treatment of recurrent vulvovaginal candidiasis, an unmet need in women’s health and onychomycosis. The company develops, manufactures, and markets injectable drugs; discovers and develops drugs for protein misfolding diseases, such as Alzheimer’s and Parkinson’s diseases. In addition, it focuses on the therapeutics areas of autoimmune and inflammatory disease, immuno-oncology, haematology, and infectious diseases; and developing medical and fitness software, and platform to eliminate disease-causing bacteria in the gut microbiota. Further, the company leverages nitric oxide's natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-medicated diseases; provides company secretarial services; develops medical devices; and offers biopharma consulting. Malin Corporation plc was incorporated in 2014 and is based in Dublin, Ireland.

Details
Name: Malin Corporation plc
MLCi
Exchange: BATS-CHIXE
Founded: 2014
€123,525,499
45,750,185
Website: http://www.malinplc.com
Address: Malin Corporation plc
The Lennox Building 50,
50 Richmond Street South,
Dublin,
Co. Dublin, D02 FK02,
Ireland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ISE MLC Ordinary Shares Irish Stock Exchange IE EUR 25. Mar 2015
OTCPK MLLN.F Ordinary Shares Pink Sheets LLC US USD 25. Mar 2015
LSE 0Y71 Ordinary Shares London Stock Exchange GB EUR 25. Mar 2015
BATS-CHIXE MLCi Ordinary Shares BATS 'Chi-X Europe' GB EUR 25. Mar 2015
Number of employees
Current staff
Staff numbers
250
Malin employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 19:51
End of day share price update: 2020/03/16 00:00
Last estimates confirmation: 2020/03/25
Last earnings filing: 2020/03/25
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.